Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

ABHD9 Inhibitors

ABHD9 Inhibitors are a specialized class of chemical compounds designed to target and inhibit the activity of the ABHD9 (Alpha/Beta-Hydrolase Domain-containing 9) enzyme, which is believed to play a role in lipid metabolism, although its specific physiological functions are still under investigation. These inhibitors function by binding to the active site of ABHD9, interfering with its enzymatic activity, which typically involves the hydrolysis of specific lipid substrates. The inhibitors achieve this by occupying the enzyme's catalytic site, preventing the natural substrates from accessing the active site and undergoing hydrolysis. This binding is often highly selective, with the inhibitors being designed to interact precisely with the structural features of ABHD9, such as its hydrophobic pockets or the catalytic triad commonly found in enzymes of the alpha/beta-hydrolase family.

The chemical composition of ABHD9 Inhibitors is critical to their effectiveness. These inhibitors are typically designed with molecular features that enhance their binding affinity to the ABHD9 enzyme. For example, they may include hydrophobic regions that interact with non-polar residues within the enzyme's active site, or they may possess polar functional groups that form hydrogen bonds with key amino acids in the catalytic triad, such as serine, histidine, or aspartate. The inhibitors might also be designed to mimic the enzyme's natural substrates, allowing them to fit snugly into the active site. Additionally, the solubility, stability, and molecular weight of these inhibitors are optimized to ensure they can efficiently reach and interact with ABHD9 in a cellular environment. The binding kinetics, including how quickly the inhibitor binds to and dissociates from ABHD9, are crucial factors that determine the overall efficacy of inhibition. By studying the interactions between ABHD9 Inhibitors and the enzyme, researchers can deepen their understanding of lipid metabolism and the biochemical pathways in which ABHD9 is involved, shedding light on its broader role within cellular processes.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lipase Inhibitor, THL

96829-58-2sc-203108
50 mg
$52.00
7
(1)

Orlistat is a lipase inhibitor that binds covalently to the serine residue of the active site in gastrointestinal lipases. When it inhibits these lipases, the hydrolysis of dietary fats is reduced. ABHD9, similar in function to other lipases, could be directly inhibited by orlistat, leading to a decrease in ABHD9's lipid metabolism activity.

Betulinic Acid

472-15-1sc-200132
sc-200132A
25 mg
100 mg
$117.00
$344.00
3
(1)

Betulinic Acid, a pentacyclic triterpenoid, inhibits various lipid metabolism enzymes. By targeting these enzymes, the compound could indirectly inhibit ABHD9 by reducing the availability of lipid substrates necessary for ABHD9's lipid metabolism function.

MAFP

188404-10-6sc-203440
5 mg
$219.00
4
(1)

Methyl arachidonyl fluorophosphonate (MAFP) is a covalent inhibitor of fatty acid amide hydrolase and other serine hydrolases. By covalently modifying the serine residue in ABHD9's active site, MAFP could lead to an irreversible inhibition of ABHD9's enzymatic activity in lipid metabolism.